Literature DB >> 15102348

Malignant gliomas.

Patrick Y Wen1, Santosh Kesari.   

Abstract

Malignant gliomas are the most common type of primary brain tumor. Although therapy for patients with these tumors remains limited, there has been important progress recently. In this review, some of these advances are discussed, with an emphasis on targeted molecular therapies.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15102348     DOI： 10.1007/s11910-004-0042-4

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN： 1528-4042            Impact factor:   6.030


  87 in total

Review 1.  Genetic and signaling pathway alterations in glioblastoma: relevance to novel targeted therapies.

Authors:  Ravi D Rao; Joon H Uhm; Sunil Krishnan; C David James
Journal:  Front Biosci       Date:  2003-05-01

2.  Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.

Authors:  O L Chinot; S Honore; H Dufour; M Barrie; D Figarella-Branger; X Muracciole; D Braguer; P M Martin; F Grisoli
Journal:  J Clin Oncol       Date:  2001-05-01       Impact factor: 44.544

Review 3.  Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: Growth factor and Ras signaling pathways.

Authors:  Herbert B Newton
Journal:  Expert Rev Anticancer Ther       Date:  2003-10       Impact factor: 4.512

4.  Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma.

Authors:  Mark R Gilbert; Jeffrey G Supko; Tracy Batchelor; Glenn Lesser; Joy D Fisher; Steven Piantadosi; Stuart Grossman
Journal:  Clin Cancer Res       Date:  2003-08-01       Impact factor: 12.531

Review 5.  The molecular target of rapamycin (mTOR) as a therapeutic target against cancer.

Authors:  Monica M Mita; Alain Mita; Eric K Rowinsky
Journal:  Cancer Biol Ther       Date:  2003 Jul-Aug       Impact factor: 4.742

6.  Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11.

Authors:  Tracy T Batchelor; Mark R Gilbert; Jeffrey G Supko; Kathryn A Carson; Louis B Nabors; Stuart A Grossman; Glenn J Lesser; Tom Mikkelsen; Surasak Phuphanich
Journal:  Neuro Oncol       Date:  2004-01       Impact factor: 12.300

7.  Expression of PDGF and PDGF receptors in human astrocytoma operation specimens supports the existence of an autocrine loop.

Authors:  A Guha; K Dashner; P M Black; J A Wagner; C D Stiles
Journal:  Int J Cancer       Date:  1995-01-17       Impact factor: 7.396

Review 8.  Invasion as limitation to anti-angiogenic glioma therapy.

Authors:  K Lamszus; P Kunkel; M Westphal
Journal:  Acta Neurochir Suppl       Date:  2003

Review 9.  Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy.

Authors:  Mariko Kawakami; Koji Kawakami; Raj K Puri
Journal:  J Neurooncol       Date:  2003-10       Impact factor: 4.130

10.  Current and Future Gene Therapy for Malignant Gliomas.

Authors:  Takao Kanzawa; Hideaki Ito; Yasuko Kondo; Seiji Kondo
Journal:  J Biomed Biotechnol       Date:  2003
View more
  11 in total

1.  EphA2 as a glioma-associated antigen: a novel target for glioma vaccines.

Authors:  Manabu Hatano; Junichi Eguchi; Tomohide Tatsumi; Naruo Kuwashima; Jill E Dusak; Michel S Kinch; Ian F Pollack; Ronald L Hamilton; Walter J Storkus; Hideho Okada
Journal:  Neoplasia       Date:  2005-08       Impact factor: 5.715

2.  Signal transduction mechanisms involved in the proliferation of C6 glioma cells induced by lysophosphatidic acid.

Authors:  Sirlene R Cechin; Peter R Dunkley; Richard Rodnight
Journal:  Neurochem Res       Date:  2005-05       Impact factor: 3.996

Review 3.  Targeted molecular therapy of malignant gliomas.

Authors:  Santosh Kesari; Naren Ramakrishna; Claire Sauvageot; Charles D Stiles; Patrick Y Wen
Journal:  Curr Neurol Neurosci Rep       Date:  2005-05       Impact factor: 5.081

Review 4.  Emerging strategies for EphA2 receptor targeting for cancer therapeutics.

Authors:  Manish Tandon; Sai Vikram Vemula; Suresh K Mittal
Journal:  Expert Opin Ther Targets       Date:  2011-01       Impact factor: 6.902

5.  Use of dentritic cells pulsed with HLA-A2-restricted MAGE-A1 peptide to generate cytotoxic T lymphocytes against malignant glioma.

Authors:  Haojun Shi; Xiaobing Jiang; Peng Fu; Yi Zhou; Xiaoling Lu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2010-11-10

Review 6.  Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.

Authors:  Nikhil G Thaker; Ian F Pollack
Journal:  Expert Rev Neurother       Date:  2009-12       Impact factor: 4.618

Review 7.  Immunotherapeutic approaches for glioma.

Authors:  Hideho Okada; Gary Kohanbash; Xinmei Zhu; Edward R Kastenhuber; Aki Hoji; Ryo Ueda; Mitsugu Fujita
Journal:  Crit Rev Immunol       Date:  2009       Impact factor: 2.214

8.  Targeted molecular therapy of malignant gliomas.

Authors:  Santosh Kesari; Naren Ramakrishna; Claire Sauvageot; Charles D Stiles; Patrick Y Wen
Journal:  Curr Oncol Rep       Date:  2006-01       Impact factor: 5.075

9.  Autotaxin and LPA receptors represent potential molecular targets for the radiosensitization of murine glioma through effects on tumor vasculature.

Authors:  Stephen M Schleicher; Dinesh K Thotala; Amanda G Linkous; Rong Hu; Kathleen M Leahy; Eugenia M Yazlovitskaya; Dennis E Hallahan
Journal:  PLoS One       Date:  2011-07-20       Impact factor: 3.240

10.  Autologous glioma cell vaccine admixed with interleukin-4 gene transfected fibroblasts in the treatment of patients with malignant gliomas.

Authors:  Hideho Okada; Frank S Lieberman; Kevin A Walter; L Dade Lunsford; Douglas S Kondziolka; Ghassan K Bejjani; Ronald L Hamilton; Alejandro Torres-Trejo; Pawel Kalinski; Quan Cai; Jennifer L Mabold; Howard D Edington; Lisa H Butterfield; Theresa L Whiteside; Douglas M Potter; S Clifford Schold; Ian F Pollack
Journal:  J Transl Med       Date:  2007-12-19       Impact factor: 5.531
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.